ID | 50627 |
フルテキストURL | |
著者 |
Kubo, Toshio
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol
Takigawa, Nagio
Kawasaki Med Univ, Dept Gen Internal Med 4
Osawa, Masahiro
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol
Harada, Daijiro
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol
Ninomiya, Takashi
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol
Ochi, Nobuaki
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol
Yamane, Hiromichi
Kawasaki Med Univ, Dept Gen Internal Med 4
Tanimoto, Mitsune
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol
Kaken ID
publons
researchmap
|
抄録 | Tumors are presumed to contain a small population of cancer stem cells (CSCs) that initiate tumor growth and promote tumor spreading. Multidrug resistance in CSCs is thought to allow the tumor to evade conventional therapy. This study focused on expression of CD133 and CD87 because CD133 is a putative marker of CSCs in some cancers including lung, and CD87 is associated with a stem-cell-like property in small-cell lung cancer (SCLC). Six SCLC cell lines were used. The expression levels of CD133 and CD87 were analyzed by real-time quantitative reverse transcription-polymerase chain reaction and flow cytometry. CD133+/- and CD87+/- cells were isolated by flow cytometry. The drug sensitivities were determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Non-obese diabetic/severe combined immunodeficiency mice were used for the tumor formation assay. SBC-7 cells showed the highest expression levels of both CD133 and CD87 among the cell lines. CD133-/CD87-, CD133+/CD87-, and CD133-/CD87+ cells were isolated from SBC-7 cells; however, CD133+/CD87+ cells could not be obtained. Both CD133+/CD87- and CD133-/CD87+ subpopulations showed a higher resistance to etoposide and paclitaxel and greater re-populating ability than the CD133-/CD87- subpopulation. CD133+/CD87- cells contained more G0 quiescent cells than CD133-/CD87- cells. By contrast, CD133-/CD87- cells showed the highest tumorigenic potential. In conclusion, both CD133 and CD87 proved to be inadequate markers for CSCs; however, they might be beneficial for predicting resistance to chemotherapy. (Cancer Sci 2013; 104: 7884)
|
発行日 | 2013-01
|
出版物タイトル |
Cancer Science
|
巻 | 104巻
|
号 | 1号
|
開始ページ | 78
|
終了ページ | 84
|
ISSN | 1347-9032
|
資料タイプ |
学術雑誌論文
|
オフィシャル URL | http://dx.doi.org/10.1111/cas.12045
|
関連URL | http://ousar.lib.okayama-u.ac.jp/metadata/50674
|
言語 |
英語
|
論文のバージョン | author
|
査読 |
有り
|
DOI | |
Web of Science KeyUT |